The U.S. Food and Drug Administration (FDA) announced on Thursday that it will begin deploying artificial intelligence (AI) internally across all its centers, with full integration scheduled for June 30. This decision follows the successful completion of a generative AI pilot program aimed at enhancing the efficiency of scientific reviewers.
Why It Matters
When the FDA receives an application for potential drug approval, it typically takes six to ten months to reach a decision. The integration of generative AI tools is expected to significantly streamline this process by reducing the time spent on repetitive and labor-intensive tasks, enabling scientists and experts to focus more on critical evaluations.
Key Statement
“Future enhancements will focus on improving usability, expanding document integration, and tailoring outputs to center-specific needs, while maintaining strict information security and compliance with FDA policy,” the FDA stated.
Context
According to a report from Wired on Wednesday, the FDA has been in talks with OpenAI to explore the application of AI technology in its regulatory processes. The discussions reportedly included multiple meetings between FDA officials, a team from OpenAI, and two associates of Elon Musk’s Department of Government Efficiency.
What’s Next?
The FDA plans to continually assess AI performance, gather user feedback, and refine its features to better meet the needs of its staff. More information about the agency’s AI deployment and future updates are expected to be made public in June.
